3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
21
Triple Negative Breast Neoplasms
12
Inflammatory Breast Neoplasms
2
Resectable HER2-positive Breast Cancer
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pathologic Complete Response
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplastic Cells, Circulating
1
Neoplasms
1
Nasopharyngeal Carcinoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Hodgkin Disease
1
HR+/HER2- Breast Cancer
1
Epstein-Barr Virus Infections
1
Down Syndrome
1
Carcinoma, Adenoid Cystic
1
CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction
1
Interventions
pembrolizumab
27
Oxaliplatin
24
Paclitaxel
22
Fluorouracil
21
Carboplatin
17
Leucovorin
16
Cisplatin
16
Capecitabine
16
Radiotherapy
15
Nivolumab
12
Drug Therapy
12
Radiation
10
Trastuzumab
9
Surgical Procedures, Operative
8
Immunotherapy
8
Magnetic Resonance Spectroscopy
7
Esophagectomy
7
Taxes
6
Blood Specimen Collection
6
tislelizumab
5
durvalumab
5
Surveys and Questionnaires
5
Specimen Handling
5
Radiotherapy, Intensity-Modulated
5
Irinotecan
5
Immune Checkpoint Inhibitors
5
Docetaxel
5
Bevacizumab
5
Ramucirumab
4
Fluorodeoxyglucose F18
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Esophageal Neoplasms
×
Epirubicin
×
1 year
×
Clear all
No trials found.